Rasna Therapeutics, Inc. Announces Follow Up Phase II Clinical Data Confirming Efficacy of Actinomycin D in Patients with NPM1-mutated Acute Myeloid Leukemia
03 January 2018
Treatment with Actinomycin D (Act D) as a single drug achieved complete remission in 4 out of 9 evaluable patients (44.4%).
Treatment with Act D at 15 µg/kg/day for 5 days every 28 days (which defines one cycle) was well tolerated...